Short answer
OptimizeRx Corp (OPRX) filed its Q2 2026 10-Q quarterly report on Aug 13, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $21M (down 29.8% year over year) with net income of −$703,000.
Q2 2026 key financials · XBRL
- Revenue
- $21M
- −29.8% YoY · +3.3% QoQ
- Net income
- −$703,000
- −145.9% YoY · −42.0% QoQ
- Operating margin
- -0.4%
- EPS (diluted)
- −$0.03
- −137.5% YoY · +0.0% QoQ
Source: XBRL data from the OptimizeRx Corp (OPRX) Q2 2026 10-Q on SEC EDGAR. USD.
OptimizeRx Corp Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $20,504, down 30% YoY from $29,195
- Operating margin (0.4%) vs 11.0% YoY, with net loss $(703) vs net income $1,532
- Cost of revenues 23% vs 36% YoY, reflecting higher-margin solution and channel mix
- Managed service program revenue declined $8,400, the weakest product area
- Cash $24,096 and operating cash flow $8,144 vs $8,425; financing used $7,368
- Near-term headwinds: measured customer spending, MFN pricing disruption, tariffs, inflation, and slower drug approvals
Risk Factors
- No material changes to 2025 Form 10-K risk factors reported
- Credit Agreement dated May 7, 2026, creates potential financing and covenant exposure
- Separation and Advisory Agreement dated June 1, 2026, indicates executive-transition risk
- Unidentified or previously immaterial risks could materially adversely affect results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OptimizeRx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.